Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Seelos Therapeutics, Inc. (SEEL : NSDQ)

• Company Description    Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $0.63 Daily Weekly Monthly 20 Day Moving Average: 1,155,619 shares Shares Outstanding: 106.09 (millions) Market Capitalization: $66.84 (millions) Beta: 2.62 52 Week High: $3.59 52 Week Low: $0.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.34% 0.37% 12 Week -40.57% -33.20% Year To Date -61.35% -52.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 300 PARK AVENUE 12TH FLOOR - NEW YORK,NY 10022 USA ph: 646-293-2100 fax: 858-436-8155 anthony.marciano@seelostx.com http://www.seelostherapeutics.com

• General Corporate Information    Officers Raj Mehra - Chief Executive Officer;Chairman of the Board Michael Golembiewski - Chief Financial Officer Margaret Dalesandro - Director Brian Lian - Director Daniel J. O'Connor - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81577F109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 106.09 Most Recent Split Date: 1.00 (0.03:1) Beta: 2.62 Market Capitalization: $66.84 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.90 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.46 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 53.57% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -91.66 12/31/21 - -108.32 09/30/21 - -95.24 ROA 03/31/22 - -72.83 12/31/21 - -86.95 09/30/21 - -75.72 Current Ratio 03/31/22 - 6.98 12/31/21 - 10.07 09/30/21 - 10.07 Quick Ratio 03/31/22 - 6.98 12/31/21 - 10.07 09/30/21 - 10.07 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.43 12/31/21 - 0.56 09/30/21 - 0.71 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.33 12/31/21 - 0.31 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 24.65 12/31/21 - 23.79 09/30/21 - 0.00

Powered by Zacks Investment Research ©